KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2025)

Bionano Genomics' Total Current Liabilities history spans 7 years, with the latest figure at $24.2 million for Q2 2025.

  • For Q2 2025, Total Current Liabilities fell 34.96% year-over-year to $24.2 million; the TTM value through Jun 2025 reached $24.2 million, down 34.96%, while the annual FY2024 figure was $37.3 million, 62.67% down from the prior year.
  • Total Current Liabilities for Q2 2025 was $24.2 million at Bionano Genomics, down from $26.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $100.0 million in Q4 2023 and bottomed at $7.2 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $33.5 million (2023), against an average of $34.8 million.
  • The largest annual shift saw Total Current Liabilities plummeted 69.08% in 2021 before it soared 178.75% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $21.8 million in 2021, then skyrocketed by 64.3% to $35.9 million in 2022, then skyrocketed by 178.75% to $100.0 million in 2023, then tumbled by 62.67% to $37.3 million in 2024, then crashed by 35.26% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Total Current Liabilities are $24.2 million (Q2 2025), $26.4 million (Q1 2025), and $37.3 million (Q4 2024).